Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
April 25, 2017
Proc Natl Acad Sci

CTD2 researchers at Dana Farber identify that 2-oxoglutarate dehydrogenase, a tricarboxylic acid cycle enzyme, is crucial to maintain PIK3CA mutant tumor survival or proliferation.

All Programs
April 03, 2017
Oncogene

Scientists demonstrate that  Phosphoinositide 3-kinase enhancer (PIKE)-A directly interacts with CDK4. Furthermore, in vitro and in vivo studies in Glioblastoma (GBM) have shown that PIKE-A/CDK4 complex promotes cell proliferation and tumorigenesis. 

CTD²
March 22, 2017
Cancer Discovery

Researchers developed a platform that integrates whole exome sequencing with high throughput drug screening in patient-derived tumor organoids. This platform has the potential to identify effective therapeutic strategies for patients where standard treatment options have been exhausted.

CTD²
March 16, 2017
Oncotarget

CTD2 scientists  at Emory University have identified Aurora Kinase A as a novel H-Ras binding partner in enhancing MAPK signaling. This novel protein-protein interaction is a potential therapeutic target in cancer.

CTD²
March 15, 2017
Marine Drugs

CTD2 researchers at University of Texas Southwestern identify marine bacteria-derived natural product N⁶,N⁶-dimethyladenosine as a potent inhibitor of Akt signaling  in non-small cell lung cancer cell lines. 

All Programs
March 06, 2017
Journal of Experimental Medicine

CTD2 scientists at CSHL characterize intratumoral heterogeneity of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.   

CTD²
February 23, 2017
Elife

Scientists at Dana Farber have performed CRISPR-Cas9 drug resistance screens and identified that loss of KEAP1 expression negates inhibitors targeting RTK/MAPK pathways in Lung cancer. This finding may assist with treatment decisions in managing lung cancer. 

CTD²
February 23, 2017
Cell Reports

CTD2 researchers at Dana Farber have identified the transcription factor ATXN1-CIC-ETS as a mediator of resistance to MAPK inhibitors in KRAS mutant pancreatic cancer cell lines using genome-scale CRISPR-Cas9 loss-Of-function screens. 

CTD²
February 22, 2017
Cancer Research

CTD2 scientists at Dana Farber have identified the serine/threonine kinase family member NEK6 as a central mediator in restoring sensitivity to hormone ablation in prostate cancer xenograft models.

CTD²
February 16, 2017
Nature Communications

The OncoPPi network is a resource of experimentally determined physical protein-protein interactions that builds on cancer genomics for discovery and exploitation of cancer vulnerabilities.   

Pages